Testing the Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Latest Information Update: 23 Feb 2024
At a glance
- Drugs CDX 1140 (Primary) ; CDX 301 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 18 Feb 2024 Status changed from recruiting to discontinued. (Celldex decision)
- 27 Feb 2021 Status changed from not yet recruiting to recruiting.
- 15 Feb 2021 Planned End Date changed from 28 Feb 2024 to 31 Mar 2024.